Investigating how CCR6-CCL20 affects colon cancer treatment response
Role of CCR6-CCL20 in biology and chemotherapeutic response in colon cancer
['FUNDING_OTHER'] · MOREHOUSE SCHOOL OF MEDICINE · NIH-11056014
This study is looking at how a specific signaling pathway in colon cancer might affect how well common chemotherapy drugs work and how they might cause side effects, with the hope of finding better and safer treatment options for patients like you.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | MOREHOUSE SCHOOL OF MEDICINE (nih funded) |
| Locations | 1 site (ATLANTA, UNITED STATES) |
| Trial ID | NIH-11056014 on ClinicalTrials.gov |
What this research studies
This research focuses on understanding the role of the CCR6-CCL20 signaling pathway in colon cancer, particularly how it influences the effectiveness of common chemotherapy drugs like 5-Fluorouracil and Oxaliplatin. By examining the molecular mechanisms behind chemotherapy resistance and toxicity, the study aims to identify new therapeutic strategies that could enhance treatment outcomes for patients. The research will involve analyzing cancer cells and tissues to assess CCR6 expression and its impact on cancer progression and response to treatment. Ultimately, the goal is to develop more effective and less toxic treatment options for colon cancer patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with colon cancer who are undergoing or considering chemotherapy treatment.
Not a fit: Patients with non-colon cancer types or those who are not receiving chemotherapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved chemotherapy options that are more effective and have fewer side effects for colon cancer patients.
How similar studies have performed: Previous research has shown promising results in targeting similar chemokine pathways for enhancing cancer treatment efficacy, indicating potential for success in this approach.
Where this research is happening
ATLANTA, UNITED STATES
- MOREHOUSE SCHOOL OF MEDICINE — ATLANTA, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: MIR, HINA ABDULREHMAN — MOREHOUSE SCHOOL OF MEDICINE
- Study coordinator: MIR, HINA ABDULREHMAN
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.